Citadel Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-65,200
| Closed | -$222K | – | 10223 |
|
|
2018
Q3 | $222K | Sell |
65,200
-78,800
| -55% | -$284K | ﹤0.01% | 8054 |
|
|
2018
Q2 | $541K | Buy |
144,000
+8,600
| +6% | +$41.9K | ﹤0.01% | 6238 |
|
|
2018
Q1 | $554K | Sell |
135,400
-164,700
| -55% | -$767K | ﹤0.01% | 5722 |
|
|
2017
Q4 | $1.4M | Buy |
300,100
+157,900
| +111% | +$870K | ﹤0.01% | 4140 |
|
|
2017
Q3 | $1.01M | Buy |
142,200
+48,800
| +52% | +$351K | ﹤0.01% | 4313 |
|
|
2017
Q2 | $675K | Buy |
93,400
+45,000
| +93% | +$281K | ﹤0.01% | 4691 |
|
|
2017
Q1 | $298K | Buy |
48,400
+8,200
| +20% | +$44.9K | ﹤0.01% | 5894 |
|
|
2016
Q4 | $236K | Buy |
40,200
+900
| +2% | +$4.92K | ﹤0.01% | 6049 |
|
|
2016
Q3 | $209K | Buy |
+39,300
| New | +$212K | ﹤0.01% | 6247 |
|
|
2016
Q2 | – | Sell |
-38,200
| Closed | -$178K | – | 7741 |
|
|
2016
Q1 | $178K | Sell |
38,200
-40,900
| -52% | -$163K | ﹤0.01% | 5722 |
|
|
2015
Q4 | $399K | Buy |
79,100
+47,000
| +146% | +$223K | ﹤0.01% | 4784 |
|
|
2015
Q3 | $113K | Sell |
32,100
-52,800
| -62% | -$354K | ﹤0.01% | 6841 |
|
|
2015
Q2 | $847K | Buy |
84,900
+20,400
| +32% | +$219K | ﹤0.01% | 4198 |
|
|
2015
Q1 | $821K | Sell |
64,500
-43,900
| -40% | -$564K | ﹤0.01% | 4203 |
|
|
2014
Q4 | $1.53M | Sell |
108,400
-145,800
| -57% | -$2.26M | ﹤0.01% | 3230 |
|
|
2014
Q3 | $3.5M | Buy |
254,200
+227,800
| +863% | +$3.49M | ﹤0.01% | 2315 |
|
|
2014
Q2 | $406K | Sell |
26,400
-5,400
| -17% | -$76.5K | ﹤0.01% | 4673 |
|
|
2014
Q1 | $542K | Sell |
31,800
-51,900
| -62% | -$783K | ﹤0.01% | 4244 |
|
|
2013
Q4 | $1.08M | Buy |
83,700
+52,300
| +167% | +$625K | ﹤0.01% | 3146 |
|
|
2013
Q3 | $317K | Sell |
31,400
-33,900
| -52% | -$302K | ﹤0.01% | 4284 |
|
|
2013
Q2 | $488K | Buy |
+65,300
| New | +$510K | ﹤0.01% | 3863 |
|
Citadel Advisors's KERX Position: Q4 2018 in Review
Citadel Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 44,686 shares — an estimated $152K sold.
Citadel Advisors first reported a position in KERX in Q2 2013 and held it in 21 quarters. The position peaked at $3.51M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Citadel Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Citadel Advisors sold 44,686 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $152K.
- Citadel Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 21 quarters.
- Citadel Advisors's Keryx Biopharmaceuticals Inc position peaked at $3.51M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.